Factors associated with Clostridium difficile diarrhea in a hospital in Beijing, China.
Clostridium difficile is the most common cause of hospital-acquired diarrhea in patients treated with antibiotics, chemotherapeutic agents, and other drugs that alter the normal equilibrium of the intestinal flora. A better understanding of the risk factors for C. difficile-associated disease (CDAD) could be used to reduce the incidence of CDAD and the costs associated with its treatment. The aim of this study was to identify the risk factors for CDAD in a cohort of Chinese patients in a Beijing hospital. Medical charts of a total of 130 inpatients (62 males and 68 females) with hospital-acquired diarrhea (45 with CDAD; 85 without CDAD) were retrospectively reviewed. C. difficile toxins A and B were detected in fecal samples using enzyme-linked fluorescence assays. The drugs used by patients with and without CDAD before the onset of diarrhea were compared. Factors that differed significantly between the two groups by univariate analysis were analyzed by multivariate analysis using a logistic regression model. Multivariate analysis showed that cephalosporin treatment was associated with a significantly higher risk of CDAD in hospitalized patients, while treatment with glycopeptides was significantly associated with a reduction in CDAD (P<0.001 for cephalosporin; P=0.013 for glycopeptides). Our data confirmed previous findings that empirical treatment with cephalosporins is positively associated with CDAD compared to individuals using other CDAD-related drugs. Additionally, we showed that treatment with glycopeptides was negatively associated with CDAD, compared to individuals using other CDAD-related drugs.
Clinical Laboratory Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
Z
Z
Lv
Clinical Laboratory Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
G L
GL
Peng
Clinical Laboratory Center, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
J R
JR
Su
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000009:adverse effects*; D001426:Bacterial Proteins / Q000302:isolation & purification; D001427:Bacterial Toxins / Q000302:isolation & purification; D002511:Cephalosporins / Q000009:adverse effects; D002681:China / Q000453:epidemiology; D016360:Clostridioides difficile / Q000472:pathogenicity*; D003428:Cross Infection / Q000453:epidemiology / Q000382:microbiology*; D003967:Diarrhea / Q000382:microbiology*; D004761:Enterocolitis, Pseudomembranous / Q000453:epidemiology / Q000382:microbiology*; D004768:Enterotoxins / Q000302:isolation & purification; D005243:Feces / Q000382:microbiology; D005260:Female; D006020:Glycopeptides / Q000627:therapeutic use; D006801:Humans; D015994:Incidence; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D012189:Retrospective Studies; D012307:Risk Factors; D018709:Statistics, Nonparametric
D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D001427:Bacterial Toxins; D002511:Cephalosporins; D004768:Enterotoxins; D006020:Glycopeptides; C041348:tcdA protein, Clostridium difficile; C031815:toxB protein, Clostridium difficile